Production (Stage)
Pangenomic Health Inc.
NARA
CNSX
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | 29.44% | -15.94% | -68.49% | -55.29% | -28.62% |
Gross Profit | -29.44% | 15.94% | 68.49% | 55.29% | 28.62% |
SG&A Expenses | -55.05% | -70.44% | -60.61% | -65.74% | -47.41% |
Depreciation & Amortization | -56.52% | -31.87% | -6.67% | 3.37% | 5.75% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -34.36% | -60.01% | -65.48% | -66.67% | -49.51% |
Operating Income | 34.36% | 60.01% | 65.48% | 66.67% | 49.51% |
Income Before Tax | -82.30% | -25.68% | 70.43% | 70.27% | 82.57% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -82.30% | -25.68% | 70.43% | 70.27% | 82.57% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -82.30% | -25.68% | 70.43% | 70.27% | 82.57% |
EBIT | 34.36% | 60.01% | 65.48% | 66.67% | 49.51% |
EBITDA | 34.22% | 60.14% | 65.71% | 66.89% | 49.68% |
EPS Basic | 35.70% | 50.77% | 88.21% | 86.94% | 87.42% |
Normalized Basic EPS | 78.08% | 80.91% | 75.89% | 75.16% | 65.74% |
EPS Diluted | 35.70% | 50.77% | 88.21% | 86.94% | 87.42% |
Normalized Diluted EPS | 78.08% | 80.91% | 75.89% | 75.16% | 65.74% |
Average Basic Shares Outstanding | 202.96% | 143.55% | 115.27% | 73.12% | 45.68% |
Average Diluted Shares Outstanding | 202.96% | 143.55% | 115.27% | 73.12% | 45.68% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |